179 related articles for article (PubMed ID: 26690485)
1. Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer.
Shimodaira S; Sano K; Hirabayashi K; Koya T; Higuchi Y; Mizuno Y; Yamaoka N; Yuzawa M; Kobayashi T; Ito K; Koizumi T
Vaccines (Basel); 2015 Dec; 3(4):1004-18. PubMed ID: 26690485
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
3. Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms' Tumor 1-Specific T Cells Induced by Dendritic Cell Vaccination.
Higuchi Y; Koya T; Yuzawa M; Yamaoka N; Mizuno Y; Yoshizawa K; Hirabayashi K; Kobayashi T; Sano K; Shimodaira S
Biomedicines; 2015 Dec; 3(4):304-315. PubMed ID: 28536414
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
[TBL] [Abstract][Full Text] [Related]
5. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines.
Hanada S; Tsuruta T; Haraguchi K; Okamoto M; Sugiyama H; Koido S
Hum Vaccin Immunother; 2019; 15(2):397-406. PubMed ID: 30230959
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer.
Ogasawara M; Miyashita M; Yamagishi Y; Ota S
Ther Apher Dial; 2019 Jun; 23(3):279-288. PubMed ID: 31033141
[TBL] [Abstract][Full Text] [Related]
8. Dendritic Cells Pre-Pulsed with Wilms' Tumor 1 in Optimized Culture for Cancer Vaccination.
Koya T; Date I; Kawaguchi H; Watanabe A; Sakamoto T; Togi M; Kato T; Yoshida K; Kojima S; Yanagisawa R; Koido S; Sugiyama H; Shimodaira S
Pharmaceutics; 2020 Mar; 12(4):. PubMed ID: 32231023
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer.
Matsuda T; Takeuchi H; Sakurai T; Mayanagi S; Booka E; Fujita T; Higuchi H; Taguchi J; Hamamoto Y; Takaishi H; Kawakubo H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
Oncol Lett; 2018 Jul; 16(1):1348-1356. PubMed ID: 29963201
[TBL] [Abstract][Full Text] [Related]
10. Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial.
Nagai K; Adachi T; Harada H; Eguchi S; Sugiyama H; Miyazaki Y
Anticancer Res; 2020 Oct; 40(10):5765-5776. PubMed ID: 32988904
[TBL] [Abstract][Full Text] [Related]
11. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
[TBL] [Abstract][Full Text] [Related]
13. Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia.
Ogasawara M; Miyashita M; Yamagishi Y; Ota S
Ther Apher Dial; 2022 Jun; 26(3):537-547. PubMed ID: 35249263
[TBL] [Abstract][Full Text] [Related]
14. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1.
Ito Z; Kan S; Bito T; Horiuchi S; Akasu T; Yoshida S; Kajihara M; Hokari A; Saruta M; Yoshida N; Kobayashi M; Ohkusa T; Shimodaira S; Okamoto M; Sugiyama H; Koido S
Oncology; 2019; 97(3):135-148. PubMed ID: 31216557
[TBL] [Abstract][Full Text] [Related]
15. Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.
Nishida S; Morimoto S; Oji Y; Morita S; Shirakata T; Enomoto T; Tsuboi A; Ueda Y; Yoshino K; Shouq A; Kanegae M; Ohno S; Fujiki F; Nakajima H; Nakae Y; Nakata J; Hosen N; Kumanogoh A; Oka Y; Kimura T; Sugiyama H
J Immunother; 2022 Jan; 45(1):56-66. PubMed ID: 34874330
[TBL] [Abstract][Full Text] [Related]
16. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based vaccine for pancreatic cancer in Japan.
Okamoto M; Kobayashi M; Yonemitsu Y; Koido S; Homma S
World J Gastrointest Pharmacol Ther; 2016 Feb; 7(1):133-8. PubMed ID: 26855819
[TBL] [Abstract][Full Text] [Related]
18. Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer.
Koido S; Homma S; Okamoto M; Takakura K; Gong J; Sugiyama H; Ohkusa T; Tajiri H
Oncoimmunology; 2014 Nov; 3(10):e958950. PubMed ID: 25941581
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer.
Ogasawara M; Miyashita M; Yamagishi Y; Ota S
Ther Apher Dial; 2020 Oct; 24(5):482-491. PubMed ID: 32524770
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
